Navigation Links
Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
Date:7/16/2008

TOKYO, and NEW DELHI, India, July 17 /PRNewswire/ -- Following intense speculation in sections of the media and the stock market, Daiichi Sankyo Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement between Daiichi Sankyo, Ranbaxy and the Singh family, the largest controlling shareholders of Ranbaxy, is binding and final, subject to regulatory approvals.

Daiichi Sankyo, Ranbaxy and the Singh family remain committed to the transaction and to the vision of creating a complementary business combination that provides sustainable growth by diversification and an enhanced global reach. Daiichi Sankyo, Ranbaxy and the Singh family stand by the deal and confirm that the terms of the deal remain unchanged. All the synergies expected to accrue to the combine, remain intact as before.

The Share Purchase and Share Subscription Agreement has earlier been unanimously approved by the Boards of Directors of both companies. Coupled with the approval now in place from the shareholders, this clears the decks for the deal to proceed as planned.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product line-up and R&D pipeline.

For more information, visit ( http://www.daiichisankyo.com/ )

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

Contact:

Daiichi Sankyo Co., Ltd.

3-5-1, Nihonbashi Honcho, Chuo-ku,

Tokyo 103-8426, Japan

Masaya Tamae

Director-Public Relations Group, Corporate Communications Department

Tel: +81-3-6225-1126

Ranbaxy

Plot 90, Sector 32, Gurgaon

Haryana122001, India

Ramesh L. Adige

Executive Director-Corporate Affairs and Global Corporate Communications

email: ramesh.adige@ranbaxy.com

Tel: +91-124-4135000

Or

Raghu Kochar

Director-Corporate Communications

email: raghu.kochar@ranbaxy.com

Tel: +91-124-4135141

Mobile: 9811617256

Or

Krishnan Ramalingam

Sr. Manager-Corporate Communications

email: krishnan.ramalingam@ranbaxy.com

Tel: +91-124-4135143

Mobile: 9810042540


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
5. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
6. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
8. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
9. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
10. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
11. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):